| Cutaneous T-Cell Lymphoma |
1 |
1 |
| Non-Hodgkin Lymphoma (NHL) |
0 |
0.8 |
| Skin Cancer |
0 |
0.9 |
| Cutaneous Lymphoma |
0 |
0.54 |
| Phototherapy |
0 |
0.53 |
| Lymphoma |
0 |
0.46 |
| Mycosis Fungoides |
0 |
0.38 |
| Refractory |
0 |
0.23 |
| Steroids |
0 |
0.23 |
| Toxicology |
0 |
0.22 |
| Patient Safety |
0 |
0.21 |
| Pain Management |
0 |
0.18 |
| Adverse Effects |
0 |
0.15 |
| Immunosuppressive Therapy |
0 |
0.15 |
| Neuropathy |
0 |
0.15 |
| Quality of Life |
0 |
0.15 |
| Topical Corticosteroid |
0 |
0.11 |
| Biologic Therapy |
0 |
0.1 |
| Genomic Medicine |
0 |
0.1 |
| Lipids Management |
0 |
0.1 |
| Stem Cell Research and Therapy |
0 |
0.1 |
| Thyroid Disease |
0 |
0.1 |
| Arizona |
0 |
0.08 |
| Child |
0 |
0.08 |
| Chronic Disease |
0 |
0.08 |
| Corticosteroids |
0 |
0.08 |
| CRISPR |
0 |
0.08 |
| Extracorporeal Photopheresis |
0 |
0.08 |
| Moisturization |
0 |
0.08 |
| Monoclonal Antibody |
0 |
0.08 |
| Pain |
0 |
0.08 |
| Pruritus |
0 |
0.08 |
| Radiation Therapy |
0 |
0.08 |
| Retinoids |
0 |
0.08 |
| Thyroid |
0 |
0.08 |
| Topical Therapy |
0 |
0.08 |